• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad, March 12 Zydus Nycomed, the 50:50 joint venture company set up by Cadila Healthcare Ltd (Zydus Cadila) and Nycomed, will now be an active pharmaceutical ingredient (API) manufacturing hub with Nycomed planning to transfer its API production from facilities at Linz (Austria) and Singen (Germany) to Zydus Nycomed in India over a period of four years.

This would result in manufacture of 18 APIs. The new development comes in the wake of the two companies deciding to expand the scope of their existing joint venture agreement and signing a letter of agreement to this effect, Zydus said in a statement here today.

Zydus Nycomed was set up in 1999 to manufacture key starting materials for the production of cost-effective Pantoprazole at their plant at Navi Mumbai.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Electrotherm launches corrosion resistant steel bars

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line